|
Human interferon gamma (hIFN-γ): Heterologously production in different expression systems and its clinical applications
|
Narjes Akbari   , Raheem Haddad * , Reza Heidari Japelaghi , Nematollah Gheibi |
| Imam Khomeini International University , r.haddad@eng.ikiu.ac.ir |
|
|
Abstract: (110 Views) |
Human interferon gamma (hIFN-γ) as a pleiotropic cytokine, modulates both innate and adaptive immune networks and is important to the function of virtually most immune cells such as macrophages and T lymphocytes. It was originally discovered, and named, as a secretory factor that interferes with viral replication. The hIFN-γ has a multitude of roles in immune modulation and broad-spectrum pathogen defense including fungal, bacterial, and viral infections. In 1986, early clinical trials of IFN-γ initiated to evaluate its therapeutic potential. The initial studies focused on the tolerability and pharmacology of IFN-γ and systematically determined its antitumor and anti-infection activities. Nowadays, it has been approved for treatment of chronic granulomatous disease and malignant osteopetrosis, and its application as an immunotherapeutic agent against cancer and inherited and autoimmune disorders is an increasing prospect. The hIFN-γ has been heterologously expressed in different expression systems including prokaryotic, protozoan, fungal (yeasts), plant, insect and mammalian cells. However, these expression systems did not reveal satisfactory results in terms of yield, the biological activity of the recombinant protein or economic viability. Thus, it is essential to find an efficient expression system to produce glycosylated recombinant hIFN-γ with correct folding, biologically active and a high half-life in the bloodstream. The review aims to gather available information from previous studies on the production of hIFN-γ and provides direction to future researches in this field.
|
|
| Keywords: hIFN-γ, Clinical trials, Cancer Immunotherapy, Recombinant protein, Expression system |
|
|
|
Type of Study: Review |
Subject:
Divers
Received: 2023/05/22 | Accepted: 2023/08/29 | Published: 2024/03/14
|
|
|
|
|
|
|
| Add your comments about this article |
|
|
|
